FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a spasmolytic agent. A spasmolytic agent comprises drotaverine hydrochloride and etaverine hydrochloride. Invention provides preparing the preparation eliciting the high spasmolytic activity that is higher as compared with that of the expected total activity of drugs used.
EFFECT: enhanced effectiveness and valuable medicinal properties of agent.
3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION SHOWING ANALGETIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND SPASMOLYTIC EFFECT | 2001 |
|
RU2183116C1 |
| DOSAGE FORM FOR RELEASING DROTAVERINE IN ORAL CAVITY | 2019 |
|
RU2729659C1 |
| INJECTION PREPARATION BASED ON DROTAVERINE AND PREPARATION METHOD THEREOF | 2015 |
|
RU2605826C1 |
| SOLUTION FOR INJECTION "NOSH-BRA" ELICITING SPASMOLYTIC EFFECT | 2001 |
|
RU2199308C1 |
| METHOD FOR OBTAINING SPASMOLYTIC MEDICINAL PREPARATION | 2003 |
|
RU2252024C2 |
| PHARMACEUTICAL COMPOSITION SHOWING SPASMOLYTIC ACTIVITY, METHOD OF ITS PREPARING | 2001 |
|
RU2183119C1 |
| SPASMOLYTIC MEDICINAL AGENT | 2002 |
|
RU2232018C2 |
| NEW THERAPEUTIC COMPOSITION FOR TREATING PAIN SYNDROME ACCOMPANYING SMOOTH MUSCLE SPASM | 2012 |
|
RU2497505C1 |
| BIODEGRADABLE SYSTEM OF TRANSMUCOSAL DELIVERY OF DROTAVERIN | 2017 |
|
RU2699808C2 |
| COMBINED ANALGESIC AND ANTI-SPASMODIC DRUG | 2012 |
|
RU2500399C2 |
